Artifactual elevation of plasma sCD40L by residual platelets in patients with coronary artery disease

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1648-1650

  Lee, Regent ^a   Antonopoulos, Alexios S ^a   Alexopoulou, Zoi ^a   Margaritis, Marios ^a   Kharbanda, Rajesh K ^a   Choudhury, Robin P ^a   Antoniades, Charalambos ^a   Channon, Keith M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cardiovascular disease; Platelets; Pre analytic; Soluble CD40 ligand

Indexed keywords

CD40 LIGAND;

AGED; CARDIOVASCULAR DISEASE; CENTRIFUGATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; INFORMED CONSENT; LETTER; LIMIT OF QUANTITATION; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ROOM TEMPERATURE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

CARDIOVASCULAR DISEASE; PLATELETS; PRE-ANALYTIC; SOLUBLE CD40 LIGAND;

ADULT; AGED; ARTIFACTS; BIOLOGICAL MARKERS; BLOOD PLATELETS; CD40 LIGAND; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION;

EID: 84885319679     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.03.019     Document Type: Article

References (10)

1. Schafer A, Wiesmann F, Neubauer S, Eigenthaler M, Bauersachs J, Channon KM. Rapid regulation of platelet activation In vivo by nitric oxide. Circulation 2004;109:1819-22.
2. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk In women. Circulation 2001;104:2266-8.
3. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand In acute coronary syndromes. N Engl J Med 2003;348:1104-11.
4. de Lemos JA, Zirlik A, Schonbeck U, et al. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2005;25:2192-6.
5. TanneD,Haim M, Goldbourt U, et al. CD40 ligand and risk of Ischemic stroke or coronary events In patients with chronic coronary heart disease. Int J Cardiol 2006;107:322-6.
6. YoshiokaT, FunayamaH, HoshinoH,etal. Association of CD40 ligand levels In the culprit coronary arteries with subsequent prognosis of acute myocardial Infarction. Atherosclerosis 2010;213:268-72.
7. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking Inflammation with atherothrombosis. J Am Coll Cardiol 2009;54:669-77.
8. Tammen H, Schulte I, Hess R, et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 2005;5:3414-22.
9. Aguilar-Mahecha A, Kuzyk MA, Domanski D, Borchers CH, Basik M. The effect of preanalytical variability on the measurement of MRM-MS-based mid-to high-abundance plasma protein biomarkers and a panel of cytokines. PLoS One 2012;7:e38290.
10. Varo N, Nuzzo R, Natal C, Libby P, Schonbeck U. Influence of pre-analytical and analytical factors on soluble CD40L measurements. Clin Sci (Lond) 2006;111:341-7.